In the competitive pharmaceutical and biotechnology industries, where robust patent portfolios are essential for protecting innovative biologics and enabling successful biosimilar development and market entry, securing favorable outcomes at the USPTO is paramount.  Patent allowance rates in pharmaceutical and biotechnology art units reveal that large pharmaceutical companies significantly outperform smaller competitors at the USPTO.

Given…